<DOC>
	<DOCNO>NCT00001060</DOCNO>
	<brief_summary>To determine safety immunization HIV-1 C4-V3 polyvalent peptide vaccine HIV-infected person . To determine proportion study participant immunize develop new specificity increase level neutralize antibody response , T-cell proliferative response , Class I restrict cytotoxic T-lymphocyte ( CTL ) responses . HIV-1 C4-V3 polyvalent peptide vaccine contain amino acid sequence select epitope four common HIV isolates United States Europe , predict represent 50-90 percent HIV isolate United States . It include epitope generate potentially salutary immune response delete epitope generate immune response might contribute immunopathogenesis .</brief_summary>
	<brief_title>A Phase I Trial HIV-1 C4-V3 Polyvalent Peptide Vaccine HIV-1 Infected Persons</brief_title>
	<detailed_description>HIV-1 C4-V3 polyvalent peptide vaccine contain amino acid sequence select epitope four common HIV isolates United States Europe , predict represent 50-90 percent HIV isolate United States . It include epitope generate potentially salutary immune response delete epitope generate immune response might contribute immunopathogenesis . Patients randomized receive low-dose high-dose HIV-1 C4-V3 polyvalent peptide vaccine incomplete Freund 's adjuvant ( IFA ) , IFA alone control . Injections administer day 0 week 4 , 8 , 12 , 24 . When patient enter low vaccine dose ( Cohort A ) reach week 6 , data review high dose cohort ( Cohort B ) begin . When cohort reach week 14 , data evaluate Cohort C begin vaccine administration choose vaccine dose . Within cohort , eight patient receive vaccine plus IFA two patient receive IFA alone . Patients follow week 52 ; 18 clinic visit four telephone call require .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Other medically indicated vaccination , provide administer least 2 week study injection . Alcohol use limit 1 oz per day 100 proof . Patients must : HIV infection without evidence AIDS . CD4 count &gt; 500 cells/mm3 . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Current evidence underlie lung liver disease . Suspected diagnosed allergy vaccine component . Medical contraindication protocol participation . Undergoing allergy skin test desensitization . Concurrent Medication : Excluded : Antiretroviral therapy ( unless clinically indicate approval investigator ) . Immunosuppressive immunomodulatory therapy . Nonsteroidal antiinflammatory agent ( except shortterm therapy acute condition ) . Drugs known hepatotoxicity . Alcohol intake &gt; 1 oz per day 100 proof . Patients follow prior condition exclude : History underlie lung disease . Abnormal chest radiograph within 2 week prior first vaccine injection . History underlie liver disease . Abnormal hepatitis B surface antigen hepatitis C antibody test within 2 week prior first vaccine injection . Abnormal liver function test within 30 day prior study entry . Evidence uveitis slit lamp exam within 2 week prior study entry . Anergic evidence negative skin test response three antigen panel consist tetanus toxoid , mumps , Candida albicans , within 6 week prior first vaccine injection . Prior participation HIV vaccine trial . Prior Medication : Excluded within past 3 month : Antiretroviral therapy . Immunosuppressive drug . Alpha interferon immunomodulatory drug . Any investigational HIV drug therapy . Current alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Vaccines , Synthetic</keyword>
	<keyword>HIV-1</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>HIV Therapeutic Vaccine</keyword>
</DOC>